Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company that develops and sells medicines for acute-care and oncology patients. Its acute-care portfolio includes ZYNRELEF, an extended-release combination of bupivacaine and meloxicam for postsurgical pain, and APONVIE, an intravenous… From the company’s description.
Over the twelve months to Jun 30, 2026, Heron Therapeutics, Inc. reported revenue of $151.18M, up 1.0% from a year earlier, and a net loss of $34.05M. Its operating margin was −7.2%, and operations used $11.61M in cash. In fiscal 2025, it reported revenue of $154.90M, up 7.4% from fiscal 2024, and a net loss of $20.20M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Heron Therapeutics, Inc. does
In the company’s own words
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company that develops and sells medicines for acute-care and oncology patients. Its acute-care portfolio includes ZYNRELEF, an extended-release combination of bupivacaine and meloxicam for postsurgical pain, and APONVIE, an intravenous aprepitant product for preventing postoperative nausea and vomiting. Its oncology portfolio includes CINVANTI, an intravenous aprepitant product used with other antiemetics to prevent chemotherapy-induced nausea and vomiting, and SUSTOL, an extended-release granisetron injection for preventing nausea and vomiting associated with chemotherapy. The company’s proprietary Biochronomer technology is designed to release medicines over days to weeks after a single administration. Heron sells its products in the United States through specialty distributors and full-line wholesalers to healthcare providers and hospitals. Its focused sales force serves surgeons, oncologists, nurses and pharmacists, while its commercial team works with healthcare accounts and payors. The U.S. sales and marketing team had 78 employees as of December 31, 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 818033
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Heron Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Heron Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Heron Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Heron Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Heron Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”